APO RESEARCH · REPORT
Human Vaccine
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.
Product & engineering
Understand the product.
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.
Selected research
Industry Research
Human Vaccine Industry Research Report 2026
Market perspective
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.
In China, Human Vaccine key players include CNBG, Kangtai, ChengDa Bio, etc. Global top three manufacturers hold a share about 65%.
East China is the largest market, with a share about 25%, followed by South China, and North China, both have a share about 40 percent.
Read the full market overview
In terms of product, Hepatitis B is the largest segment, with a share nearly 15%. And in terms of application, the largest application is Children, followed by Adults.
Report Scope
This report quantifies the global Human Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (M Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Vaccine Market by Company
CNBG
Changsheng Life
Zhifei
ChengDa Bio
Kangtai
SINOVAC BIOTECH
Hissen
Walvax Biotechnology
GSK
SANOFI
Rong An
NuoCheng Bio
Hualan Bio
Tiantan biological
Changchun Baike
Adimmune
Zhongyianke Biotech
Bharat Biotech
Bavarian Nordic
Sanofi-Pasteur
Indian Immunologicals
KANGH
Henan Grand Biopharma
ZhongKe Biopharm
Zhuoyi Biological
Human Vaccine Segment by Type
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, Tetanus
Pneumococcal
Rota vaccine
Human Vaccine Segment by Application
Adults
Children
Human Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Varicella
- Influenza
- Polio
- Hepatitis A
- Rabies
- BCG
- Hepatitis B
- Pertussis, Diphtheria, Tetanus
- Pneumococcal
- Rota vaccine
Applications
- Adults
- Children
Companies covered
- CNBG
- Changsheng Life
- Zhifei
- ChengDa Bio
- Kangtai
- SINOVAC BIOTECH
- Hissen
- Walvax Biotechnology
- GSK
- SANOFI
- Rong An
- NuoCheng Bio
- Hualan Bio
- Tiantan biological
- Changchun Baike
- Adimmune
- Zhongyianke Biotech
- Bharat Biotech
- Bavarian Nordic
- Sanofi-Pasteur
- Indian Immunologicals
- KANGH
- Henan Grand Biopharma
- ZhongKe Biopharm
- Zhuoyi Biological
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Vaccine Market Size (2021-2032)
- 2.2.2 Global Human Vaccine Sales (2021-2032)
- 2.2.3 Global Human Vaccine Market Average Price (2021-2032)
- 2.3 Human Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Varicella
- 2.3.3 Influenza
- 2.3.4 Polio
- 2.3.5 Hepatitis A
- 2.3.6 Rabies
- 2.3.7 BCG
- 2.3.8 Hepatitis B
- 2.3.9 Pertussis, Diphtheria, Tetanus
- 2.3.10 Pneumococcal
- 2.3.11 Rota vaccine
- 2.4 Human Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adults
- 2.4.3 Children
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Vaccine Sales (M Doses) of Manufacturers (2021-2026)
- 3.3 Global Human Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Human Vaccine, Established Date
- 3.9 Global Human Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CNBG
- 4.1.1 CNBG Company Information
- 4.1.2 CNBG Business Overview
- 4.1.3 CNBG Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CNBG Human Vaccine Product Portfolio
- 4.1.5 CNBG Recent Developments
- 4.2 Changsheng Life
- 4.2.1 Changsheng Life Company Information
- 4.2.2 Changsheng Life Business Overview
- 4.2.3 Changsheng Life Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Changsheng Life Human Vaccine Product Portfolio
- 4.2.5 Changsheng Life Recent Developments
- 4.3 Zhifei
- 4.3.1 Zhifei Company Information
- 4.3.2 Zhifei Business Overview
- 4.3.3 Zhifei Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Zhifei Human Vaccine Product Portfolio
- 4.3.5 Zhifei Recent Developments
- 4.4 ChengDa Bio
- 4.4.1 ChengDa Bio Company Information
- 4.4.2 ChengDa Bio Business Overview
- 4.4.3 ChengDa Bio Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 ChengDa Bio Human Vaccine Product Portfolio
- 4.4.5 ChengDa Bio Recent Developments
- 4.5 Kangtai
- 4.5.1 Kangtai Company Information
- 4.5.2 Kangtai Business Overview
- 4.5.3 Kangtai Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kangtai Human Vaccine Product Portfolio
- 4.5.5 Kangtai Recent Developments
- 4.6 SINOVAC BIOTECH
- 4.6.1 SINOVAC BIOTECH Company Information
- 4.6.2 SINOVAC BIOTECH Business Overview
- 4.6.3 SINOVAC BIOTECH Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 SINOVAC BIOTECH Human Vaccine Product Portfolio
- 4.6.5 SINOVAC BIOTECH Recent Developments
- 4.7 Hissen
- 4.7.1 Hissen Company Information
- 4.7.2 Hissen Business Overview
- 4.7.3 Hissen Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hissen Human Vaccine Product Portfolio
- 4.7.5 Hissen Recent Developments
- 4.8 Walvax Biotechnology
- 4.8.1 Walvax Biotechnology Company Information
- 4.8.2 Walvax Biotechnology Business Overview
- 4.8.3 Walvax Biotechnology Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Walvax Biotechnology Human Vaccine Product Portfolio
- 4.8.5 Walvax Biotechnology Recent Developments
- 4.9 GSK
- 4.9.1 GSK Company Information
- 4.9.2 GSK Business Overview
- 4.9.3 GSK Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 GSK Human Vaccine Product Portfolio
- 4.9.5 GSK Recent Developments
- 4.10 SANOFI
- 4.10.1 SANOFI Company Information
- 4.10.2 SANOFI Business Overview
- 4.10.3 SANOFI Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 SANOFI Human Vaccine Product Portfolio
- 4.10.5 SANOFI Recent Developments
- 4.11 Rong An
- 4.11.1 Rong An Company Information
- 4.11.2 Rong An Business Overview
- 4.11.3 Rong An Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Rong An Human Vaccine Product Portfolio
- 4.11.5 Rong An Recent Developments
- 4.12 NuoCheng Bio
- 4.12.1 NuoCheng Bio Company Information
- 4.12.2 NuoCheng Bio Business Overview
- 4.12.3 NuoCheng Bio Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 NuoCheng Bio Human Vaccine Product Portfolio
- 4.12.5 NuoCheng Bio Recent Developments
- 4.13 Hualan Bio
- 4.13.1 Hualan Bio Company Information
- 4.13.2 Hualan Bio Business Overview
- 4.13.3 Hualan Bio Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Hualan Bio Human Vaccine Product Portfolio
- 4.13.5 Hualan Bio Recent Developments
- 4.14 Tiantan biological
- 4.14.1 Tiantan biological Company Information
- 4.14.2 Tiantan biological Business Overview
- 4.14.3 Tiantan biological Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Tiantan biological Human Vaccine Product Portfolio
- 4.14.5 Tiantan biological Recent Developments
- 4.15 Changchun Baike
- 4.15.1 Changchun Baike Company Information
- 4.15.2 Changchun Baike Business Overview
- 4.15.3 Changchun Baike Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Changchun Baike Human Vaccine Product Portfolio
- 4.15.5 Changchun Baike Recent Developments
- 4.16 Adimmune
- 4.16.1 Adimmune Company Information
- 4.16.2 Adimmune Business Overview
- 4.16.3 Adimmune Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Adimmune Human Vaccine Product Portfolio
- 4.16.5 Adimmune Recent Developments
- 4.17 Zhongyianke Biotech
- 4.17.1 Zhongyianke Biotech Company Information
- 4.17.2 Zhongyianke Biotech Business Overview
- 4.17.3 Zhongyianke Biotech Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Zhongyianke Biotech Human Vaccine Product Portfolio
- 4.17.5 Zhongyianke Biotech Recent Developments
- 4.18 Bharat Biotech
- 4.18.1 Bharat Biotech Company Information
- 4.18.2 Bharat Biotech Business Overview
- 4.18.3 Bharat Biotech Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Bharat Biotech Human Vaccine Product Portfolio
- 4.18.5 Bharat Biotech Recent Developments
- 4.19 Bavarian Nordic
- 4.19.1 Bavarian Nordic Company Information
- 4.19.2 Bavarian Nordic Business Overview
- 4.19.3 Bavarian Nordic Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Bavarian Nordic Human Vaccine Product Portfolio
- 4.19.5 Bavarian Nordic Recent Developments
- 4.20 Sanofi-Pasteur
- 4.20.1 Sanofi-Pasteur Company Information
- 4.20.2 Sanofi-Pasteur Business Overview
- 4.20.3 Sanofi-Pasteur Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Sanofi-Pasteur Human Vaccine Product Portfolio
- 4.20.5 Sanofi-Pasteur Recent Developments
- 4.21 Indian Immunologicals
- 4.21.1 Indian Immunologicals Company Information
- 4.21.2 Indian Immunologicals Business Overview
- 4.21.3 Indian Immunologicals Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 Indian Immunologicals Human Vaccine Product Portfolio
- 4.21.5 Indian Immunologicals Recent Developments
- 4.22 KANGH
- 4.22.1 KANGH Company Information
- 4.22.2 KANGH Business Overview
- 4.22.3 KANGH Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.22.4 KANGH Human Vaccine Product Portfolio
- 4.22.5 KANGH Recent Developments
- 4.23 Henan Grand Biopharma
- 4.23.1 Henan Grand Biopharma Company Information
- 4.23.2 Henan Grand Biopharma Business Overview
- 4.23.3 Henan Grand Biopharma Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.23.4 Henan Grand Biopharma Human Vaccine Product Portfolio
- 4.23.5 Henan Grand Biopharma Recent Developments
- 4.24 ZhongKe Biopharm
- 4.24.1 ZhongKe Biopharm Company Information
- 4.24.2 ZhongKe Biopharm Business Overview
- 4.24.3 ZhongKe Biopharm Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.24.4 ZhongKe Biopharm Human Vaccine Product Portfolio
- 4.24.5 ZhongKe Biopharm Recent Developments
- 4.25 Zhuoyi Biological
- 4.25.1 Zhuoyi Biological Company Information
- 4.25.2 Zhuoyi Biological Business Overview
- 4.25.3 Zhuoyi Biological Human Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.25.4 Zhuoyi Biological Human Vaccine Product Portfolio
- 4.25.5 Zhuoyi Biological Recent Developments
5 Global Human Vaccine Market Scenario by Region
- 5.1 Global Human Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Human Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Human Vaccine Sales by Region: 2027-2032
- 5.3 Global Human Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Human Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Human Vaccine Revenue by Region: 2027-2032
- 5.4 North America Human Vaccine Market Facts & Figures by Country
- 5.4.1 North America Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Human Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Human Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Human Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Human Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Vaccine Market Facts & Figures by Country
- 5.7.1 South America Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Human Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Human Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Human Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Human Vaccine Sales by Type (2021-2032) & (M Doses)
- 6.1.2 Global Human Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Human Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Human Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Human Vaccine Sales by Application (2021-2032) & (M Doses)
- 7.1.2 Global Human Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Human Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Human Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Vaccine Value Chain Analysis
- 8.1.1 Human Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Vaccine Production Mode & Process
- 8.2 Human Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Vaccine Distributors
- 8.2.3 Human Vaccine Customers
9 Global Human Vaccine Analyzing Market Dynamics
- 9.1 Human Vaccine Industry Trends
- 9.2 Human Vaccine Industry Drivers
- 9.3 Human Vaccine Industry Opportunities and Challenges
- 9.4 Human Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst